3m big tick for potential if trials are good

I* was talking to an uncle about this, I am 38 he is 64 and has been involved in a few listed biotechs over the years. I asked him to have a look at last weeks news. His response was a big tick for OBJ getting in the door and also being lucky enough for 3m to look at the patch let alone doing testing etc etc. he said that he had had devices and so on that he had [presented to big companies (but none like 3m, more like resmed and co) and they get presented to so often that its really difficult to even get a look in.In the end he said if the trial goes well then OBJ will fly or get gobbled up, if not then his sentiments were they will most likely head back to current levels or less, a punt worth taking though given the upside potential. I thought I would share this with you guys as as much as we might speculate now, it all comes down to how good these patches are. I have great respect for charts etc but this has the "potential" to kick those out the door.